Boston Sci’s ELUVIA Drug Eluting Stent Cleared in Europe
 

Boston Sci’s ELUVIA Drug Eluting Stent Cleared in Europe
http://www.medgadget.com/wp-content/.../02/ELUVIA.jpg

Boston Scientific got hold of a CE mark to introduce the ELUVIA drug eluting vascular stent in Europe. Designed for delivery into the leg arteries above the knee, the*superficial femoral and proximal popliteal, the polymer stent keeps the lumen open by releasing*paclitaxel that prevents reste**sis.

From Boston Sci:

CE Mark approval was based on data from the MAJESTIC trial, a prospective, multicenter clinical trial that assessed the safety and performance of the Eluvia Stent System and reflected a primary patency rate of more than 96 percent1. *The MAJESTIC trial results represented the highest 12-month primary patency reported for an interventional treatment of femoropopliteal artery lesions among comparable trials.

Boston Scientific received an Investigational Device Exemption (IDE) to conduct a global, prospective trial called the IMPERIAL trial, which will assess the safety and efficacy of the Eluvia Stent System compared to the Zilver® PTX® Stent manufactured by Cook Medical. Enrollment began in Q4 last year and the study will include approximately 485 patients in 75 sites worldwide.

Via:*Boston Scientific…

The post Boston Sci’s ELUVIA Drug Eluting Stent Cleared in Europe appeared first on Medgadget.

http://feeds.feedburner.com/~ff/Medgadget?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/Medgadget?d=qj6IDK7rITs http://feeds.feedburner.com/~ff/Medg...a0:gIN9vFwOqvQ
http://feeds.feedburner.com/~r/Medgadget/~4/I_4Uyy4Q93s